Results 261 to 270 of about 8,658,473 (396)

Key role for inhibins in effective T cell activation, migration and Th17 differentiation

open access: yesFEBS Open Bio, EarlyView.
Activins/inhibins modulate immune responses. Here, we show that inhibins can be produced very early after T cell activation and can act in an autocrine way, favoring Th1 versus Th17 differentiation and CCL19/CCL21 mediated migration. Recombinant inhibin A can restore the Th1/Th17 balance, highlighting the role of inhibins as key regulators of T cell ...
Sandra Ortega‐Francisco   +5 more
wiley   +1 more source

THE CATABOLISM OF URACIL IN VIVO AND IN VITRO

open access: hybrid, 1954
Robert J. Rutman   +2 more
openalex   +1 more source

Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024

open access: yesFEBS Open Bio, EarlyView.
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior   +5 more
wiley   +1 more source

Organoids as an in vitro model of human development and disease

open access: yesNature Cell Biology, 2016
A. Fatehullah, Si Hui Tan, N. Barker
semanticscholar   +1 more source

BCS1L‐Associated Disease: 5′‐UTR Variant Shifts the Phenotype Towards Axonal Neuropathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives To investigate the consequences of a pathogenic missense variant (c.838C>T; p.L280F) and a 5′‐UTR regulatory variant (c.‐122G>T) in BCS1L on disease pathogenesis and to understand how regulatory variants influence disease severity and clinical presentation.
Rotem Orbach   +11 more
wiley   +1 more source

In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell
Benjamin J. Murdock   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy